SEARCH

SEARCH BY CITATION

References

  • 1
    Plosker GL, Foster RH. Tacrolimus: A further update of its pharmacology and therapeutic use in the management of organ transplantation. Drugs 2000; 59: 323389.
  • 2
    Starzl TE, Todo S, Fung J, Demtris AJ, Venkataramman R, Jain A. FK506 for liver, kidney, and pancreas transplantation. Lancet 1989; 2: 10001004.
  • 3
    Baran DA, Galin I, Sandler D et al. Tacrolimus in cardiac transplantation: Efficacy and safety of a novel dosing protocol. Transplantation 2002; 74: 11361141.
  • 4
    Armitage JM, Kormos RL, Morita S et al. Clinical trial of FK506 immunosuppression in adult cardiac transplantation. Ann Thorac Surg 1992; 54: 205211.
  • 5
    Pham SM, Kormos RL, Hattler BG et al. A prospective trial of tacrolimus (FK506) in clinical heart transplantation: Intermediate-term results. J Thorac Cardiovasc Surg 1996; 111: 764772.
  • 6
    Taylor DO, Barr ML, Radovancevic B et al. A randomized, multicenter comparison of tacrolimus and cyclosporine immunosuppressive regimens in cardiac transplantation: Decreased hyperlipidemia and hypertension with tacrolimus. J Heart Lung Transplant 1999; 18: 336345.
  • 7
    Reichart B, Meiser B, Vigano M et al. European multicenter tacrolimus (FK506) heart pilot study: One-year results—European tacrolimus multicenter heart study group. J Heart Lung Transplant 1998; 17: 775781.
  • 8
    Kobashigawa J, Miller L, Renlund D et al. A randomized active-control trial of mycophenolate mofetil in heart transplant recipients. Transplantation 1998; 66: 507515.
  • 9
    Keogh A, Richardson M, Ruygrok P et al. Sirolimus in de novo heart transplant recipients reduces acute rejection and prevents coronary artery disease at 2 years. A randomized clinical trial. Circulation 2004; 110: r10r16.
  • 10
    Eisen HJ, Tuczu EM, Dorent R et al. Everolimus for the prevention of allograft rejection and vasculopathy in cardiac-transplant patients. N Engl J Med 2003; 349: 847858.
  • 11
    Billingham ME, Cary NR, Hammond EM et al. A working formulation for standardization of nomenclature in the diagnosis of heart and lung rejection study group. The International Society for Heart Transplantation. J Heart Transplant 1990; 9: 587593.
  • 12
    Hertz MI, Taylor DO, Trulock EP et al. The Registry of the International Society for Heart and Lung Transplantation: Nineteenth official report—2002. J Heart Lung Transplant 2002; 21: 950970.
  • 13
    Jurcevic S, Dunn MJ, Crisp S et al. A new enzyme-linked immunoabsorbent assay to measure anti-endothelial antibodies after cardiac transplantation demonstrates greater inhibition of antibody formation by tacrolimus compared with cyclosporine. Transplantation 1998; 65: 11971202.
  • 14
    Kobashigawa JA, Moriguchi JD, Takemoto S et al. First year results of a randomized trial of tacrolimus vs. neoral cyclosporine in heart transplant patients [abstract]. J Heart Lung Transplant 2000; 19: 47.
  • 15
    De Bonis M, Reynolds L, Barros J, Madden BP. Tacrolimus as a rescue immunosuppressant after heart transplantation. Eur J Cardiothorac Surg 2001; 19: 690695.
  • 16
    Yamani MH, Starling RC, Pelegrin D et al. Efficacy of tacrolimus in patients with steroid-resistant cardiac allograft cellular rejection. J Heart Lung Transplant 2000; 19: 337342.
  • 17
    Mathieu P, Carrier M, White M et al. Conversion of cyclosporine A to tacrolimus following heart transplantation. Can J Cardiol 1999; 15: 12291232.
  • 18
    Meiser BM, Überfuhr P, Fuchs A et al. Tacrolimus: A superior agent to OKT3 for treating cases of persistent rejection after intrathoracic transplantation. J Heart Lung Transplant 1997; 16: 795800.
  • 19
    Escobar A, Ventura HO, Stapleton DD et al. Cardiac allograft vasculopathy assessed by intravascular ultrasonography and nonimmunologic risk factors. Am J Cardiol 1994; 74: 10421046.
  • 20
    Kobashigawa J, Katznelson S, Laks H et al. Effect of pravastatin on outcomes after cardiac transplantation. N Engl J Med 1995; 333: 621627.
  • 21
    Meisner BM, Überfuhr P, Fuchs A et al. Single-center randomized trial comparing tacrolimus (FK506) and cyclosporine in the prevention of acute myocardial rejection. J Heart Lung Transplant 1998; 17: 782788.
  • 22
    Marelli S, Laks H, Patel B et al. Heart transplantation in patients with diabetes mellitus in the current era. J Heart Lung Transplant 2003; 22: 10911097.
  • 23
    Czerny M, Sahin V, Fashing P et al. The impact of diabetes mellitus at the time of heart transplantation on long-term survival. Diabetologia 2002; 45: 14981508.
  • 24
    Lang CC, Beniaminovitz A, Edwards N, Mancini DM. Morbidity and mortality in diabetic patients following cardiac transplantation. J Heart Lung Transplant 2003; 22: 244249.
  • 25
    Teebken OE, Struber M, Harringer W et al. Primary immunosuppression with tacrolimus and mycophenolate mofetil vs cyclosporine and azathioprine in heart transplant recipients. Transplant Proc 2002; 34: 12651268.
  • 26
    Keogh A, The Sirolimus Cardiac Transplant Trial Group. Sirolimus immunotherapy reduces the rates of cardiac allograft rejection: 6-month results from a phase 2, open-label study [abstract]. Am J Transplant 2002; 2 (Suppl 3): 246.
  • 27
    Kauffman HM, Cherikh WSS, McBride MA et al. TOR inhibitor maintenance immunosuppression is associated with a reduced incidence of post-transplant malignancies [abstract]. Transplant 2004; 78: 30.
  • 28
    Hesselink DA, Van Gelder T. The influence of cyclosporine on mycophenolic acid concentrations: A review. Transplant Rev 2003; 17: 158163.